Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status
The IMID Forum
00:00
Analysis of Upadacitinib treatment for Non-Radiographic Axial Spondyloarthritis
The chapter presents a study where patients with Non-Radiographic Axial Spondyloarthritis were treated with upadacitinib or a placebo, showing significant improvement in disease activity and sustained clinical efficacy of upadacitinib over 52 weeks with no new safety concerns.
Transcript
Play full episode
